Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • I-BET-762: Selective BET Bromodomain Inhibitor for Inflam...

    2026-02-19

    I-BET-762: Selective BET Bromodomain Inhibitor for Inflammation and Cancer Research

    Executive Summary: I-BET-762 (SKU B1498) is a potent, selective inhibitor of the BET family of bromodomain proteins, with IC50 values ranging from 32.5 to 42.5 nM and high binding affinity (Kd 50.5–61.3 nM) for the acetyl-lysine pocket (APExBIO). Its 2:1 binding stoichiometry confers strong selectivity, with minimal off-target effects on non-BET bromodomains. I-BET-762 downregulates LPS-inducible gene expression, showing anti-inflammatory efficacy in vivo and reducing cytokine production. Recent studies confirm it enhances erastin-induced ferroptosis in multiple cancer cell lines by promoting ROS accumulation and FSP1 downregulation (Fan et al., 2024). Its robust solubility in DMSO and ethanol, along with precise storage requirements, make it a reliable tool for epigenetic, inflammation, and cancer research workflows.

    Biological Rationale

    The bromodomain and extra-terminal domain (BET) family regulates gene expression by recognizing acetylated lysine residues on histones. BET proteins, such as BRD4, serve as epigenetic readers, influencing transcriptional programs central to inflammation, immune response, and oncogenesis (Fan et al., 2024). Dysregulation of BET signaling is linked to pathological states including chronic inflammation and various cancers. Selective BET inhibition represents a targeted approach for modulating transcription of disease-relevant genes without broadly suppressing global acetylation marks. I-BET-762 is engineered to exploit this mechanism, enabling specific interrogation and modulation of BET-driven pathways in preclinical models.

    Mechanism of Action of I-BET-762

    I-BET-762 is a small-molecule inhibitor that competitively binds to the acetyl-lysine (AcK) recognition pocket of BET proteins, particularly BRD2, BRD3, and BRD4. This interaction disrupts BET-mediated chromatin recruitment, thereby impeding transcription of genes under BET regulation. The compound exhibits a binding stoichiometry of 2:1 with BET proteins, enhancing its selectivity and affinity, and shows no significant activity against non-BET bromodomain-containing proteins (APExBIO). In cellular models, I-BET-762 downregulates LPS-inducible cytokines and chemokines by suppressing promoter activity of inflammatory genes. In cancer biology, the compound potentiates ferroptosis when used in combination with inducers such as erastin, primarily by increasing reactive oxygen species (ROS) and downregulating ferroptosis suppressor protein 1 (FSP1), as demonstrated in multiple human cell lines (Fan et al., 2024).

    Evidence & Benchmarks

    • I-BET-762 binds BET proteins with high affinity (Kd 50.5–61.3 nM) and selectivity, as characterized by displacement assays and biophysical studies (APExBIO).
    • The compound competitively displaces acetyl-lysine from BET proteins, with IC50 values of 32.5–42.5 nM in biochemical assays (APExBIO).
    • I-BET-762 displays no significant cross-reactivity with non-BET bromodomains, minimizing off-target effects (APExBIO).
    • In LPS-stimulated macrophage models, I-BET-762 downregulates expression of inflammatory cytokines and chemokines, demonstrating anti-inflammatory activity in vivo (APExBIO).
    • BRD4 inhibition by I-BET-762 enhances erastin-induced ferroptosis in HEK293T, HeLa, HepG2, RKO, and PC3 cancer cell lines, accompanied by increased ROS and reduced FSP1 protein levels (Fan et al., 2024).
    • ChIP-seq data confirm reduced BRD4 binding at the FSP1 promoter after I-BET-762 treatment, linking BET inhibition with ferroptosis regulation (Fan et al., 2024).

    For a deeper dive into molecular and translational mechanisms, see "I-BET-762 and the Future of BET Bromodomain Inhibition: Mechanistic and Translational Insights". This article extends the current discussion by integrating the latest mechanistic findings on ferroptosis and gene regulation.

    For detailed protocol optimization and assay guidance, refer to "I-BET-762 (SKU B1498): Practical Solutions for BET Inhibitor Assays", which this article updates by incorporating new evidence on FSP1 modulation and ROS dynamics in different cancer cell lines.

    Applications, Limits & Misconceptions

    I-BET-762 is widely used as a selective BET bromodomain inhibitor for inflammation research, epigenetic regulation, and cancer biology. Its efficacy in modulating transcriptional regulation of LPS-inducible genes makes it valuable for anti-inflammatory studies in preclinical models. In oncology, it is an effective adjunct for promoting ferroptosis in FSP1-dependent cancer cell lines (Fan et al., 2024).

    Common Pitfalls or Misconceptions

    • I-BET-762 does not inhibit non-BET bromodomain proteins; its selectivity does not extend to all bromodomain-containing proteins (APExBIO).
    • The compound is insoluble in water and requires DMSO or ethanol (with sonication) for proper dissolution; attempts at aqueous solubilization result in precipitation and loss of activity (APExBIO).
    • Prolonged storage of solutions at room temperature leads to degradation; use solutions promptly and store at -20°C (APExBIO).
    • I-BET-762 efficacy in promoting ferroptosis is cell-type dependent and may not be generalizable to cell lines lacking FSP1 dependence (Fan et al., 2024).
    • It is not designed or approved for clinical use in humans; research use only (APExBIO).

    For strategic guidance on integrating I-BET-762 into preclinical workflows and benchmarking against other BET inhibitors, see "I-BET-762: Strategic BET Bromodomain Inhibition for Next-Generation Research". This resource provides a broader context of competitive BET inhibitor use and differentiates I-BET-762 within the field.

    Workflow Integration & Parameters

    I-BET-762 is supplied as a solid compound with a molecular weight of 423.9 g/mol and chemical formula C22H22ClN5O2 (APExBIO). For experimental use, dissolve at concentrations ≥21.19 mg/mL in DMSO or ≥13.93 mg/mL in ethanol (with ultrasonic assistance). The compound is insoluble in water. Aliquots should be stored at -20°C, and solutions prepared immediately before use to preserve activity.

    In cell-based assays, typical working concentrations range from 0.1 to 5 μM, with 1–2 μM commonly used for BRD4 inhibition in proliferation, viability, and ferroptosis assays. For optimal results, validate solubility and activity in intended model systems. I-BET-762 is compatible with standard cell viability assays, flow cytometry, and gene expression analysis workflows. For detailed scenario-driven protocol recommendations, see "I-BET-762 (SKU B1498): Practical Solutions for BET Inhibitor Assays".

    Conclusion & Outlook

    I-BET-762, developed and distributed by APExBIO, is a validated, selective BET bromodomain inhibitor with robust performance in preclinical models of inflammation and cancer. Its nanomolar potency, strong selectivity, and compatibility with modern research workflows position it as a leading tool for dissecting BET protein signaling and its physiological consequences. Current evidence underscores its value in both anti-inflammatory research and ferroptosis modulation in cancer biology. Ongoing studies will further clarify its role in combinatorial epigenetic and ferroptosis-targeting strategies.

    For full technical specifications, ordering information, and up-to-date documentation, visit the I-BET-762 product page.